Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?

por Licht, Jonathan D.
Publicado 2001

SETD2: a complex role in blood malignancy

por Licht, Jonathan D.
Publicado en Blood (2017)

DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A

por LICHT, JONATHAN D.
Publicado en Trans Am Clin Climatol Assoc (2018)

Emerging Epigenetic Targets and Therapies in Cancer Medicine

por Popovic, Relja, Licht, Jonathan D.
Publicado 2012

Molecular Pathways: Deregulation of Histone 3 Lysine 27 Methylation in Cancer—Different Paths, Same Destination

por Ezponda, Teresa, Licht, Jonathan D.
Publicado 2014

HOX deregulation in acute myeloid leukemia

por Rice, Kim L., Licht, Jonathan D.
Publicado 2007

PARTNERS IN CRIME: GENES WITHIN AN AMPLICON COLLUDE TO GLOBALLY DEREGULATE CHROMATIN In LYMPHOMA

por Min, Dong-Joon, Licht, Jonathan D.
Publicado 2010

Consequences of oncogenic isocitrate dehydrogenase mutations and 2-hydroxyglutarate production in prostate epithelium

por Over, Jon A, Licht, Jonathan D
Publicado 2013

FQI1: a transcription-methylation switch for cancer

por Guryanova, Olga A., Licht, Jonathan D.
Publicado en Oncotarget (2017)

Epigenetic Regulatory Mutations and Epigenetic Therapy For Multiple Myeloma

por Dupéré-Richer, Daphné, Licht, Jonathan D.
Publicado en Curr Opin Hematol (2017)

TARGETING EPIGENETICS IN CANCER

por Bennett, Richard L., Licht, Jonathan D.
Publicado en Annu Rev Pharmacol Toxicol (2017)

Leveraging epigenetics to enhance the efficacy of immunotherapy

por Licht, Jonathan D., Bennett, Richard L.
Publicado en Clin Epigenetics (2021)

From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma

por Licht, Jonathan D., Shortt, Jake, Johnstone, Ricky
Publicado 2014

Epigenetic therapy of hematological malignancies: where are we now?

por Popovic, Relja, Shah, Mrinal Y., Licht, Jonathan D.
Publicado 2013

New Strategies in Acute Myeloid Leukemia: Redefining prognostic markers to guide therapy

por Khan, Irum, Altman, Jessica K., Licht, Jonathan D.
Publicado 2012

Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity

por Alzrigat, Mohammad, Jernberg-Wiklund, Helena, Licht, Jonathan D.
Publicado en Epigenomes (2018)

Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells

por Polo, Jose M., Ci, Weimin, Licht, Jonathan D., Melnick, Ari
Publicado 2008

Spry1 and Spry2 are necessary for eyelid closure

por Kuracha, Murali R., Siefker, Ed, Licht, Jonathan D., Govindarajan, Venkatesh
Publicado 2013

Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis

por Arcipowski, Kelly M., Bulic, Marinka, Gurbuxani, Sandeep, Licht, Jonathan D.
Publicado en PLoS One (2016)

The Role of Nuclear Receptor–Binding SET Domain Family Histone Lysine Methyltransferases in Cancer

por Bennett, Richard L., Swaroop, Alok, Troche, Catalina, Licht, Jonathan D.
Publicado en Cold Spring Harb Perspect Med (2017)